Navigation Links
Third Wave responds to Digene patent lawsuit

Madison, Wis. - Responding to a lawsuit filed by Digene Corp., Third Wave Technologies said it has not violated a patent covering a single and rare type of the human papilloma virus (HPV) and would continue to develop products to detect high-risk infections.
Full article >>> y grants of licenses or money changing hands. At that time, the companies agreed not to sue each other for a year.

To remove ambiguities about its freedom to operate in the HPV and HCV (hepatitis C virus) markets, Third Wave has settled suits with several companies.

......

Full article >>>
'"/>

Source:wistechnology.com By WTN News 01/12/07


Related biology technology :

1. Third Wave files countersuit vs. Digene in patent case
2. Third Wave reports net loss of $18.9M for 2006
3. Stratagene to pay Third Wave $10.75M in patent case
4. Third Wave seeks approval of Cystic Fibrosis test
5. Third Wave Technologies to raise $14.9M through private debt
6. Third Wave reports $5.2M third quarter loss
7. Third Wave reports another loss, stronger sales
8. Napier joins board of Third Wave Technologies
9. Third Waves revenues rebound
10. Third Wave reports clinical growth, continued loss
11. Third Wave announces two senior management appointments
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... CLEVELAND , June 27, 2016  Global ... average 4.6 percent through 2020 to $7.2 billion.  ... (food and beverages, cleaning products, biofuel production, animal ... and biotechnology, diagnostics, and biocatalysts). Food and beverages ... gains driven by increasing consumption of products containing ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... bring innovative medical technologies, services and solutions to the healthcare market. The company's ... of various distribution, manufacturing, sales and marketing strategies that are necessary to help ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
Breaking Biology News(10 mins):